Nasdaq:CAPR
CAPRICOR THERAPEUTICS, INC.
A clinical-stage biopharmaceutical company specializing in precision oncology and rare disease treatments via its CapriDx platform.
Key Metrics
Investment Thesis
Bull Case
Investors may view Capricor Therapeutics as a high-potential speculative play given its innovative CapriDx platform and focus on rare diseases which often command higher reimbursement rates. The company's ability to secure substantial financing inflows demonstrates continued investor confidence in its long-term development pipeline despite current cash burn. Successful clinical trials or strategic partnerships could unlock significant value, potentially transforming the company from a capital-intensive R&D entity into a profitable biopharmaceutical business.
Bear Case
The stock carries substantial risk due to a net profit deficit of $40.5 million and a retained earnings deficit of nearly $200 million, signaling ongoing financial distress. With cash and equivalents at only $11.3 million against negative operating cash flow, the company faces an imminent liquidity crunch without further dilutive fundraising or successful asset sales. The declining revenue trend from 2023 to 2024 raises concerns about the sustainability of its business model and the ability to generate meaningful commercial returns from its pipeline.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics focuses on developing novel therapeutic candidates for rare diseases and oncology, leveraging its proprietary CapriDx platform to advance precision medicine. The company serves markets in the United States and internationally through its pipeline of antibody-drug conjugates (ADCs) and gene therapies. Key products under development target specific molecular pathways to address unmet medical needs in high-value therapeutic areas.
Analysis
Management Discussion
Management reported a net loss of $40.5 million for the latest period, driven by substantial research and development expenditures totaling $50.0 million and operating expenses reaching $64.8 million. While cash flow from financing activities provided a significant inflow of $152.8 million through share issuances, this was partially offset by investing outflows of $116.2 million. The reduction in revenue compared to the prior year suggests that the company is still navigating the early stages of commercializing its pipeline or managing transition periods within its partnership agreements.
Industry Overview
The biotechnology sector is currently characterized by intense competition, high regulatory standards, and a heavy emphasis on innovation through novel drug mechanisms like ADCs. Companies in this space often require continuous capital investment to navigate clinical trials before achieving product approvals and commercial success. Market dynamics favor firms with proprietary platforms that can accelerate development timelines and reduce overall costs while targeting underserved patient populations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.6M | $25.2M | $22.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.6M | $25.2M | $22.3M |
| Operating Expenses | $32.2M | $49.3M | $64.8M |
| Operating Income | $-29.7M | $-24.1M | $-42.6M |
| R&D | $21.8M | $36.4M | $50.0M |
| G&A | $10.4M | $12.8M | $14.9M |
| Stock-Based Comp | — | $7.4M | $9.8M |
| D&A | — | $1.1M | $1.4M |
| Depreciation | — | $1.1M | $1.4M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-29.7M | $-24.1M | $-42.6M |
| Income Tax | $-677.9K | $-1.8M | $-2.1M |
| Continuing Ops | $-29.0M | $-22.3M | $-40.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-29.0M | $-22.3M | $-40.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-29.0M | $-22.3M | $-40.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $42.9M | $50.9M | $163.4M |
| Cash & Equivalents | $9.6M | $14.7M | $11.3M |
| Marketable Securities | $31.8M | $24.8M | $140.2M |
| Prepaid Expenses | $919.9K | $995.8K | $1.5M |
| Other Current Assets | $547.6K | $10.4M | $10.4M |
| Long-Term Assets | $7.2M | $7.9M | $7.1M |
| PP&E (Net) | $4.6M | $5.6M | $5.6M |
| Operating Leases | $2.3M | $2.1M | $1.3M |
| Other LT Assets | $268.2K | $268.2K | $221.7K |
| Total Assets | $50.1M | $58.7M | $170.5M |
| Current Liabilities | $23.6M | $31.3M | $21.0M |
| Current Leases | $682.0K | $749.1K | $834.8K |
| Deferred Revenue | $18.0M | $24.3M | $12.0M |
| Other Current Liab | $4.9M | $6.3M | $8.2M |
| Long-Term Liabilities | $14.7M | $4.9M | $4.0M |
| LT Operating Leases | $1.9M | $1.5M | $616.3K |
| Other LT Liab | $3.4M | $3.4M | $3.4M |
| Total Liabilities | $38.3M | $36.1M | $25.0M |
| Shareholders' Equity | $11.8M | $22.6M | $145.5M |
| Retained Earnings | $-137.1M | $-159.4M | $-199.8M |
| AOCI | $105.2K | $235.8K | $1.0M |
| Total L&E | $50.1M | $58.7M | $170.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | — | $-22.3M | $-40.5M |
| Non-Cash Adjustments | — | $-1.5M | $10.3M |
| Working Capital Changes | — | $-1.8M | $-9.9M |
| Cash from Operations | — | $-25.6M | $-40.0M |
| Capital Expenditures | — | $1.3M | $1.2M |
| Cash from Investing | — | $5.1M | $-116.2M |
| Cash from Financing | — | $25.6M | $152.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | — | $5.1M | $-3.4M |
| Beginning Cash | — | $9.6M | $14.7M |
| Ending Cash | — | $14.7M | $11.3M |
Frequently Asked Questions
How does CAPRICOR THERAPEUTICS, INC. make money?
The company's revenue is primarily derived from collaborations with academic institutions and pharmaceutical partners for the development of its antibody-drug conjugate (ADC) candidates. Operations are segmented by therapeutic area focus, including oncology and rare diseases, with significant R&D spending directed toward advancing clinical-stage assets. Financial data indicates a reliance on non-operating financing activities to fund research and development efforts while generating minimal operating cash flow.
What are the main risks for CAPR?
The company operates at a significant net loss with accumulated deficits exceeding $199 million, indicating a heavy reliance on external financing to sustain operations. Cash flow from operations was negative $40 million in 2024, and cash burn rates remain high relative to current cash reserves of $11.3 million. Revenue volatility is evident with a sharp decline from $25.2 million in 2023 to $22.3 million in 2024, suggesting potential challenges in sustaining commercial partnerships or generating product sales. The biotechnology sector faces regulatory hurdles and long development timelines that could delay or prevent the commercialization of key pipeline assets.
What is CAPR's competitive advantage?
The CapriDx platform enables the discovery of novel targets and the rapid development of highly selective antibody-drug conjugates (ADCs) with reduced toxicity profiles. The company benefits from strategic collaborations with leading academic institutions, providing access to diverse patient populations and cutting-edge research capabilities. A lean organizational structure allows for efficient capital deployment despite high clinical trial costs in the biotechnology sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.